{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:52:49Z","timestamp":1791139969073,"version":"4.1.0"},"reference-count":83,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2000,12,1]],"date-time":"2000-12-01T00:00:00Z","timestamp":975628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Neurofibromatosis type 1 (NF1) represents a major risk factor for development of malignancy, particularly malignant peripheral nerve sheath tumors (MPNST), optic gliomas, other gliomas, and leukemias. The oncologist will see NF1 patients referred for treatment of malignancy, and should be alert to the possibility of undiagnosed NF1 among patients with cancer. Brain tumors tend to have a more indolent course in NF1 than in the general population, and hence are best managed conservatively. MPNST, in contrast, do not respond to standard chemotherapy or radiation therapy. The most effective treatment of MPNST appears to be early diagnosis and surgery, but early diagnosis is hampered by frequent occurrence within preexisting large tumors, making new growth or change difficult to detect. New insights into pathogenesis now offer hope of development of specific methods of treatment with reduced toxicity and more precise molecular targeting. There is an urgent need, however, to develop methods to measure tumor growth and monitor outcomes, develop preclinical drug screening systems, and further explore the pathogenesis of the disorder to determine whether mechanisms other than Ras regulation may be important in pathogenesis.<\/jats:p>","DOI":"10.1634\/theoncologist.5-6-477","type":"journal-article","created":{"date-parts":[[2004,8,24]],"date-time":"2004-08-24T21:38:39Z","timestamp":1093383519000},"page":"477-485","source":"Crossref","is-referenced-by-count":264,"title":["Malignancy in Neurofibromatosis Type 1"],"prefix":"10.1093","volume":"5","author":[{"given":"Bruce R.","family":"Korf","sequence":"first","affiliation":[{"name":"Partners Center for Human Genetics, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2000,12,1]]},"reference":[{"key":"2021122210022590900_R1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0092-8674(90)90253-B","article-title":"A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations","volume":"62","author":"Cawthon","year":"1990","journal-title":"Cell"},{"key":"2021122210022590900_R2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/0888-7543(90)90199-5","article-title":"Identification and characterization of transcripts from the neurofibromatosis 1 region: the sequence and genomic structure of EVI2 and mapping of other transcripts","volume":"7","author":"Cawthon","year":"1990","journal-title":"Genomics"},{"key":"2021122210022590900_R3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0092-8674(90)90252-A","article-title":"Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus","volume":"62","author":"Viskochil","year":"1990","journal-title":"Cell"},{"key":"2021122210022590900_R4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1126\/science.2134734","article-title":"Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients","volume":"249","author":"Wallace","year":"1990","journal-title":"Science"},{"key":"2021122210022590900_R5","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0092-8674(90)90149-9","article-title":"The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae","volume":"63","author":"Xu","year":"1990","journal-title":"Cell"},{"key":"2021122210022590900_R6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/0092-8674(90)90024-9","article-title":"The neurofibromatosis type 1 gene encodes a protein related to GAP","volume":"62","author":"Xu","year":"1990","journal-title":"Cell"},{"key":"2021122210022590900_R7","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0092-8674(90)90150-D","article-title":"The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21","volume":"63","author":"Martin","year":"1990","journal-title":"Cell"},{"key":"2021122210022590900_R8","first-page":"841","article-title":"A functional assay for heterozygous mutations in the GTPase activating protein related domain of the neurofibromatosis type 1 gene","volume":"10","author":"Ishioka","year":"1995","journal-title":"Oncogene"},{"key":"2021122210022590900_R9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/archneur.1988.00520290115023","article-title":"Neurofibromatosis","volume":"45","author":"Stumpf","year":"1988","journal-title":"Arch Neurol"},{"key":"2021122210022590900_R10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jama.1997.03550010065042","article-title":"The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2","volume":"278","author":"Gutmann","year":"1997","journal-title":"JAMA"},{"key":"2021122210022590900_R11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s004390050317","article-title":"Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene","volume":"99","author":"Upadhyaya","year":"1997","journal-title":"Hum Genet"},{"key":"2021122210022590900_R12","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1086\/302809","article-title":"Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain","volume":"66","author":"Fahsold","year":"2000","journal-title":"Am J Hum Genet"},{"key":"2021122210022590900_R13","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1212\/WNL.54.8.1646","article-title":"Use of \u201cunidentified bright objects\u201d on MRI for diagnosis of neurofibromatosis 1 in children","volume":"54","author":"DeBella","year":"2000","journal-title":"Neurology"},{"key":"2021122210022590900_R14","first-page":"271","article-title":"Penetrance and variability in neurofibromatosis: a genetic study of 60 families","volume":"15","author":"Carey","year":"1979","journal-title":"Birth Defects Original Article Series"},{"key":"2021122210022590900_R15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/(SICI)1096-8628(1997)73:2<197::AID-AJMG17>3.0.CO;2-P","article-title":"Familial neurofibromatosis 1 microdeletions: cosegregation with distinct facial phenotype and early onset of cutaneous neurofibromata","volume":"73","author":"Leppig","year":"1997","journal-title":"Am J Med Genet"},{"key":"2021122210022590900_R16","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/ajmg.1320590427","article-title":"Deletion of the entire NF1 gene detected by FISH: four deletion patients associated with severe manifestations","volume":"59","author":"Wu","year":"1995","journal-title":"Am J Med Genet"},{"key":"2021122210022590900_R17","first-page":"33","article-title":"Malignancy in neurofibromatosis","volume":"29","author":"Hope","year":"1981","journal-title":"Adv Neurol"},{"key":"2021122210022590900_R18","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/1097-0142(19860315)57:6<1225::AID-CNCR2820570627>3.0.CO;2-P","article-title":"Neurofibromatosis and childhood tumors","volume":"57","author":"Blatt","year":"1986","journal-title":"Cancer"},{"key":"2021122210022590900_R19","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/brain\/111.6.1355","article-title":"Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales","volume":"111","author":"Huson","year":"1988","journal-title":"Brain"},{"key":"2021122210022590900_R20","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/(SICI)1096-8628(19970516)70:2<138::AID-AJMG7>3.0.CO;2-U","article-title":"Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients","volume":"70","author":"Friedman","year":"1997","journal-title":"Am J Med Genet"},{"key":"2021122210022590900_R21","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJM198604173141603","article-title":"Long-term follow-up of von Recklinghausen neurofibromatosis survival and malignant neoplasms","volume":"314","author":"Sorensen","year":"1986","journal-title":"N Engl J Med"},{"key":"2021122210022590900_R22","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1002\/1097-0142(19931101)72:9<2746::AID-CNCR2820720936>3.0.CO;2-W","article-title":"Neurofibromatosis type 1 and childhood cancer","volume":"72","author":"Matsui","year":"1993","journal-title":"Cancer"},{"key":"2021122210022590900_R23","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1212\/WNL.39.4.487","article-title":"Neurofibromatosis and other disorders among children with CNS tumors and their families","volume":"39","author":"Baptiste","year":"1989","journal-title":"Neurology"},{"key":"2021122210022590900_R24","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/1097-0142(196308)16:8<1015::AID-CNCR2820160808>3.0.CO;2-I","article-title":"Sarcomas of the peripheral nerves and somatic soft tissues associated with multiple neurofibromatosis (von Recklinghausen's disease)","volume":"16","author":"D'Agostino","year":"1963","journal-title":"Cancer"},{"key":"2021122210022590900_R25","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1002\/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6","article-title":"Malignant peripheral nerve sheath tumors. A clinicopathological study of 120 cases","volume":"57","author":"Ducatman","year":"1986","journal-title":"Cancer"},{"key":"2021122210022590900_R26","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/1097-0142(19930215)71:4<1247::AID-CNCR2820710413>3.0.CO;2-S","article-title":"Malignant peripheral nerve sheath tumors. A clinicopathologic study of 28 cases","volume":"71","author":"Wanebo","year":"1993","journal-title":"Cancer"},{"key":"2021122210022590900_R27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1097-0142(19870101)59:1<1::AID-CNCR2820590105>3.0.CO;2-A","article-title":"Treatment of children with neurogenic sarcoma. Experience at the Children's Hospital of Philadelphia, 1958-1984","volume":"59","author":"Raney","year":"1987","journal-title":"Cancer"},{"key":"2021122210022590900_R28","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0748-7983(05)80073-3","article-title":"Malignant peripheral nerve sheath tumors in patients with and without neurofibromatosis","volume":"21","author":"Doorn","year":"1995","journal-title":"Eur J Surg Oncol"},{"key":"2021122210022590900_R29","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/mpo.2950220203","article-title":"Neurofibromatosis type I and malignancy: review of 32 pediatric cases treated at a single institution","volume":"22","author":"Shearer","year":"1994","journal-title":"Med Pediatr Oncol"},{"key":"2021122210022590900_R30","first-page":"352","article-title":"Detection of malignant change in neurofibromatosis (von Recklinghausen's disease) by gallium-67 scanning","volume":"119","author":"Hammond","year":"1978","journal-title":"Can Med Assoc J"},{"key":"2021122210022590900_R31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jnnp.68.3.353","article-title":"Evaluation of (18)fluorodeoxyglucose positron emission tomography (18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1","volume":"68","author":"Ferner","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021122210022590900_R32","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/ng0293-122","article-title":"Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis","volume":"3","author":"Legius","year":"1993","journal-title":"Nat Genet"},{"key":"2021122210022590900_R33","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/ng0995-90","article-title":"Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene","volume":"11","author":"Colman","year":"1995","journal-title":"Nat Genet"},{"key":"2021122210022590900_R34","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1172\/JCI7610","article-title":"Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models","volume":"105","author":"DeClue","year":"2000","journal-title":"J Clin Invest"},{"key":"2021122210022590900_R35","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0161-6420(84)34217-8","article-title":"von Recklinghausen neurofibromatosis. II. Incidence of optic gliomata","volume":"91","author":"Lewis","year":"1984","journal-title":"Ophthalmology"},{"key":"2021122210022590900_R36","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0022-3476(94)70122-9","article-title":"Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study","volume":"125","author":"Listernick","year":"1994","journal-title":"J Pediatr"},{"key":"2021122210022590900_R37","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1542\/peds.100.4.667","article-title":"Endocrinologic disorders and optic pathway gliomas in children with neurofibromatosis type 1","volume":"100","author":"Cnossen","year":"1997","journal-title":"Pediatrics"},{"key":"2021122210022590900_R38","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0022-3476(95)70449-3","article-title":"Precocious puberty in children with neurofibromatosis type 1","volume":"126","author":"Habiby","year":"1995","journal-title":"J Pediatr"},{"key":"2021122210022590900_R39","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/bjo.53.12.793","article-title":"Optic glioma of childhood. Natural history and rationale for conservative management","volume":"53","author":"Hoyt","year":"1969","journal-title":"Br J Ophthalmol"},{"key":"2021122210022590900_R40","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1055\/s-2008-1073043","article-title":"Follow-up of optic pathway gliomas in children with neurofibromatosis type 1","volume":"25","author":"Kuenzle","year":"1994","journal-title":"Neuropediatrics"},{"key":"2021122210022590900_R41","first-page":"173","article-title":"Optic gliomas in neurofibromatosis type 1 (NF-1). Presentation of 31 cases","volume":"9","author":"Pascual-Castroviejo","year":"1994","journal-title":"Neurologia"},{"key":"2021122210022590900_R42","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0022-3476(05)81151-5","article-title":"Emergence of optic pathway gliomas in children with neurofibromatosis type 1 after normal neuroimaging results","volume":"121","author":"Listernick","year":"1992","journal-title":"J Pediatr"},{"key":"2021122210022590900_R43","first-page":"1711","article-title":"Spontaneous involution of optic pathway lesions in neurofibromatosis type 1: serial contrast MR evaluation","volume":"16","author":"Parazzini","year":"1995","journal-title":"AJNR Am J Neuroradiol"},{"key":"2021122210022590900_R44","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0887-8994(94)90043-4","article-title":"Optic gliomas in neurofibromatosis type 1: role of visual evoked potentials","volume":"10","author":"North","year":"1994","journal-title":"Pediatr Neurol"},{"key":"2021122210022590900_R45","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/BF00303606","article-title":"Early diagnosis of optic glioma in children with neurofibromatosis type 1","volume":"10","author":"Rossi","year":"1994","journal-title":"Childs Nerv Sys"},{"key":"2021122210022590900_R46","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/ana.410410204","article-title":"Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force","volume":"41","author":"Listernick","year":"1997","journal-title":"Ann Neurol"},{"key":"2021122210022590900_R47","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/adc.76.3.259","article-title":"Visual pathway glioma: an erratic tumour with therapeutic dilemmas","volume":"76","author":"Shuper","year":"1997","journal-title":"Arch Dis Child"},{"key":"2021122210022590900_R48","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000120729","article-title":"Optic pathway\/hypothalamic gliomas: a dilemma in management","volume":"19","author":"Hoffman","year":"1993","journal-title":"Pediatr Neurosurg"},{"key":"2021122210022590900_R49","first-page":"1114","article-title":"Prognostic significance of type 1 neurofibromatosis (von Recklinghausen Disease) in childhood optic glioma","volume":"38","author":"Deliganis","year":"1996","journal-title":"Neurosurgery"},{"key":"2021122210022590900_R50","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0360-3016(93)90342-S","article-title":"Optic glioma in children: surveillance, resection, or irradiation","volume":"25","author":"Jenkin","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122210022590900_R51","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1212\/WNL.36.9.1173","article-title":"Moyamoya pattern of vascular occlusion after radiotherapy for glioma of the optic chiasm","volume":"36","author":"Beyer","year":"1986","journal-title":"Neurology"},{"key":"2021122210022590900_R52","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3171\/jns.1993.79.1.0032","article-title":"Moyamoya phenomenon after radiation for optic glioma","volume":"79","author":"Kestle","year":"1993","journal-title":"J Neurosurg"},{"key":"2021122210022590900_R53","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1023\/A:1006338322266","article-title":"Carboplatin therapy for optic pathway tumors in children with neurofibromatosis type-1","volume":"45","author":"Listernick","year":"1999","journal-title":"J Neurooncol"},{"key":"2021122210022590900_R54","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ana.410230113","article-title":"Treatment of chiasmatic\/hypothalamic gliomas of childhood with chemotherapy: an update","volume":"23","author":"Packer","year":"1988","journal-title":"Ann Neurol"},{"issue":"part 1","key":"2021122210022590900_R55","first-page":"331","article-title":"Gliomas in neurofibromatosis: a series of 89 cases with evidence for enhanced malignancy in associated cerebellar astrocytomas","volume":"20","author":"Ilgren","year":"1985","journal-title":"Pathol Annu"},{"key":"2021122210022590900_R56","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF02147094","article-title":"Favorable prognosis for brain stem gliomas in neurofibromatosis","volume":"7","author":"Milstein","year":"1989","journal-title":"J Neurooncol"},{"key":"2021122210022590900_R57","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1212\/WNL.46.6.1652","article-title":"The management of brain stem gliomas in patients with neurofibromatosis","volume":"46","author":"Pollack","year":"1996","journal-title":"Neurology"},{"key":"2021122210022590900_R58","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1212\/WNL.45.10.1897","article-title":"Brainstem tumors in patients with neurofibromatosis type 1: a distinct clinical entity","volume":"45","author":"Molloy","year":"1995","journal-title":"Neurology"},{"key":"2021122210022590900_R59","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0022-3476(78)80362-X","article-title":"Neurofibromatosis and childhood leukemia","volume":"92","author":"Bader","year":"1978","journal-title":"J Pediatr"},{"key":"2021122210022590900_R60","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/bjc.1994.431","article-title":"Neurofibromatosis and childhood leukaemia\/lymphoma: a population-based UKCCSG study","volume":"70","author":"Stiller","year":"1994","journal-title":"Br J Cancer"},{"key":"2021122210022590900_R61","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1001\/archderm.1995.01690200040007","article-title":"Juvenile xanthogranuloma, neurofibromatosis, and juvenile chronic myelogenous leukemia. World statistical analysis","volume":"131","author":"Zvulunov","year":"1995","journal-title":"Arch Dermatol"},{"key":"2021122210022590900_R62","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJM199403033300903","article-title":"Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders","volume":"330","author":"Shannon","year":"1994","journal-title":"N Engl J Med"},{"key":"2021122210022590900_R63","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/blood.V84.10.3435.3435","article-title":"Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras","volume":"84","author":"Kalra","year":"1994","journal-title":"Blood"},{"key":"2021122210022590900_R64","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/ng0296-144","article-title":"Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells","volume":"12","author":"Bollag","year":"1996","journal-title":"Nat Genet"},{"key":"2021122210022590900_R65","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1097-2765(00)80415-3","article-title":"Nf1 and Gmcsf interact in myeloid leukemogenesis","volume":"5","author":"Birnbaum","year":"2000","journal-title":"Mol Cell"},{"key":"2021122210022590900_R66","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1084\/jem.187.11.1893","article-title":"Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines","volume":"187","author":"Zhang","year":"1998","journal-title":"J Exp Med"},{"key":"2021122210022590900_R67","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/hmg\/6.11.1979","article-title":"Point mutations in human GLI3 cause Greig syndrome","volume":"6","author":"Wild","year":"1997","journal-title":"Hum Mol Genet"},{"key":"2021122210022590900_R68","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/1097-0142(197706)39:6<2550::AID-CNCR2820390636>3.0.CO;2-Y","article-title":"The relationship between nephroblastoma and neurofibromatosis (von Recklinghausen's disease)","volume":"39","author":"Stay","year":"1977","journal-title":"Cancer"},{"key":"2021122210022590900_R69","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.1985.3.1.117","article-title":"Synchronous neuroblastoma and von Recklinghausen's disease: a review of the literature","volume":"3","author":"Kushner","year":"1985","journal-title":"J Clin Oncol"},{"key":"2021122210022590900_R70","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0165-4608(86)90216-5","article-title":"Childhood neurofibromatosis: risk factors for malignant disease","volume":"21","author":"Schneider","year":"1986","journal-title":"Cancer Genet Cytogenet"},{"key":"2021122210022590900_R71","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/ng0794-353","article-title":"Tumour predisposition in mice heterozygous for a targeted mutation in NF1","volume":"7","author":"Jacks","year":"1994","journal-title":"Nat Genet"},{"key":"2021122210022590900_R72","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/nar\/24.3.478","article-title":"The neurofibromatosis type 1 messenger RNA undergoes base-modification RNA editing","volume":"24","author":"Skuse","year":"1996","journal-title":"Nucleic Acids Res"},{"key":"2021122210022590900_R73","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1126\/science.286.5447.2176","article-title":"Mouse tumor model for neurofibromatosis type 1","volume":"286","author":"Vogel","year":"1999","journal-title":"Science"},{"key":"2021122210022590900_R74","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/gcc.2870100405","article-title":"TP53 mutations are frequent in malignant NF1 tumors","volume":"10","author":"Legius","year":"1994","journal-title":"Genes Chromosomes Cancer"},{"key":"2021122210022590900_R75","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0092-8674(92)90407-4","article-title":"Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis","volume":"69","author":"DeClue","year":"1992","journal-title":"Cell"},{"key":"2021122210022590900_R76","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/molehr\/4.10.978","article-title":"Pregnancy after preimplantation genetic diagnosis for Charcot-Marie-Tooth disease type 1A","volume":"4","author":"Vos","year":"1998","journal-title":"Mol Hum Reprod"},{"key":"2021122210022590900_R77","first-page":"3569","article-title":"Farnesyltransferase inhibitors block the neurofibromatosis type 1 (NF1) malignant phenotype","volume":"55","author":"Yan","year":"1995","journal-title":"Cancer Res"},{"key":"2021122210022590900_R78","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1128\/MCB.17.2.862","article-title":"NF1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase","volume":"17","author":"Kim","year":"1997","journal-title":"Mol Cell Biol"},{"key":"2021122210022590900_R79","first-page":"1871","article-title":"A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity","volume":"60","author":"Adjei","year":"2000","journal-title":"Cancer Res"},{"key":"2021122210022590900_R80","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1200\/JCO.2000.18.4.927","article-title":"Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer","volume":"18","author":"Zujewski","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122210022590900_R81","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1006\/excr.1996.0297","article-title":"NF1 mRNA isoform expression in PC12 cells: modulation by extrinsic factors","volume":"228","author":"Metheny","year":"1996","journal-title":"Exp Cell Res"},{"key":"2021122210022590900_R82","first-page":"292","article-title":"Inhibition of ras oncogene: a novel approach to antineoplastic therapy","volume":"7","author":"Scharovsky","year":"2000","journal-title":"J Biomed Sci"},{"key":"2021122210022590900_R83","first-page":"577","article-title":"Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice","volume":"53","author":"Gray","year":"1993","journal-title":"Cancer Res"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.5-6-477","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.5-6-477","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/5\/6\/477\/41837438\/oncolo_5_6_477.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/5\/6\/477\/41837438\/oncolo_5_6_477.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T18:05:30Z","timestamp":1640196330000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/5\/6\/477\/6385845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,12,1]]},"references-count":83,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2000,12,1]]},"published-print":{"date-parts":[[2000,12,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.5-6-477","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2000,12,1]]},"published":{"date-parts":[[2000,12,1]]}}}